secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-276060
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris Q3 net loss narrows to $11.9M; cash $77M; Phase 1a data on track for year-end
--------------------------------------------------------------------------------

- Phase 1a SAD trial initial clinical data (safety, efficacy, PK) expected by year end 2025.
- Phase 1b/2 MAD trial in nAMD enrolling up to 80 patients; initial data expected 2H 2026.
- Cash, cash equivalents and ST investments $77.0M as of Sept 30, 2025; expected to fund operations into 2027.
- R&D expense $9.1M (vs $36.0M in Q3 2024); net loss $11.9M (vs $38.1M).
- Selected KBI Biopharma as CDMO; hired CFO Matthew Gall; opened NJ headquarters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525276060/0001193125-25-276060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525276060/d70447d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-276060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer